MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
BeiGene, Ltd. Operating Cash Flow 2011-2026 | BGNE
Annual Operating Cash Flow BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 B | -141 M | -1.16 B | -1.5 B | -1.3 B | -1.28 B | -750 M | -548 M | 12.8 M | -89.5 M | -39.8 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 B | -1.5 B | -515 M |
Quarterly Operating Cash Flow BeiGene, Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 44.1 M | - | - | - | -309 M | - | - | - | -564 M | - | -1.18 B | -617 M | -237 M | - | -791 M | -295 M | 125 M | - | -951 M | -605 M | -342 M | - | -483 M | -218 M | -172 M | - | -354 M | -222 M | -105 M | - | -81 M | -87.6 M | -35.7 M | - | -63.4 M | -39.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 125 M | -1.18 B | -330 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Nanobiotix S.A.
NBTX
|
-29.9 M | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M |  USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
68 M | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.49 | 1.36 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-177 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
InflaRx N.V.
IFRX
|
-39.9 M | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Immutep Limited
IMMP
|
-17.6 M | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-10.6 M | $ 3.83 | -2.3 % | $ 258 B | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.81 | -1.16 % | $ 27.9 M | Israel |
 |
Baudax Bio
BXRX
|
-27.8 M | - | 0.59 % | $ 63 K | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Cabaletta Bio
CABA
|
-131 M | $ 3.13 | -1.26 % | $ 315 M | USA |